Philippe Halfon,1,2 Sophie Ravet,3 Hacène Khiri,1 Guillaume Penaranda,1,2,3 and Carole Lefoll2 1 Laboratoire Alphabio, Marseille, France 2 Hopital Ambroise Paré, Marseille, France 3 CDL Pharma, Marseille, France Corresponding author email: philippe.halfon@alphabio.fr This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. Abstract We report the case of a 19-year-old woman who received a complete vaccine […]
Impact of Improved Classification on the Association of Human Papillomavirus
Philip E. Castle*, Mark Schiffman, Cosette M. Wheeler, Nicolas Wentzensen, and Patti E. Gravitt Initially submitted June 1, 2009; accepted for publication August 5, 2009. Correspondence to Dr. Philip E. Castle, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Room 5004, MSC 7234, Bethesda, MD 20892-7234 (e-mail: castlep@mail.nih.gov). Misclassification of exposure […]
HPV Testing for Patients with Atypical Squamous Cells Identifies Those at High Risk for Cancer
By: Barbara Boughton 02 November 2010 (San Francisco, California) — A new study from an inner-city hospital in Atlanta, Georgia, of 348 patients with a diagnosis of atypical squamous cells of undetermined significance (ASC-US) confirms that high-risk human papillomavirus (HPV) assay testing is essential for pinpointing patients with high-grade dysplasia who need follow-up treatment, according […]
